18F-FDG PET/CT in Lung Cancer

Agrawal, Archi; Rangarajan, Venkatesh; Purandare, Nilendu

doi:10.1007/978-3-319-72661-8_5

Cited by 3 publications

(13 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Over time, SCLC was counted as a systemic disease and stratified as limited or extensive disease in consistent with the modified version of the Veterans Administration Lung Cancer Study Group (VALSG) staging system and that is because at the initial diagnosis, about 60%–70% of cases with SCLC have metastases. 7 Limited stage (LS) is defined as disease confined to one hemi-thorax, includes involvement of mediastinal, contralateral hilar and/or supraclavicular and scalene lymph nodes. Extensive disease is defined as disease with spread beyond the definition of LS or the existence of malignant pleural effusion.…”

Section: Sclc Stagingmentioning

confidence: 99%

“…In this edition, a change in the therapeutic management of patients with SCLC with more emphasis in curative intent has been taken into consideration, which is now a preferential choice. 7 …”

Section: Sclc Stagingmentioning

confidence: 99%

“…SCLC is characterized by high aggressiveness with rapid doubling time and dissemination at the time of the initial diagnosis. 7 It is estimated at around 15%–20% of all lung cancers. The discrimination of LS and extensive stage (ES) is crucial on the basis of whether the disease is limited to one hemi-thorax or is disseminated.…”

Section: Sclc Investigationmentioning

confidence: 99%

“…PET/CT also changes the stage and the therapeutic management in 12%–26% of SCLC patients. 7 The global scientific literature does not provide enough data for SCLC and PET/CT.…”

Section: Sclc Investigationmentioning

confidence: 99%

“…Lung cancer can be diagnosed from the symptoms of primary tumor, local spread, metastases from inappropriate, or ectopic hormone excretion. 7 …”

Section: Diagnosismentioning

confidence: 99%

See 4 more Smart Citations

Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review

et al. 2020

View full text Add to dashboard Cite

Introduction: In this study, we evaluated the use and the contribution of radiopharmaceuticals to the field of lung neoplasms imaging using positron emission tomography/computed tomography. Methods: We conducted review of the current literature at PubMed/MEDLINE until February 2020. The search language was English. Results: The most widely used radiopharmaceuticals are the following: Experimental/pre-clinical approaches: (18)F-Misonidazole (18F-MISO) under clinical development, D(18)F-Fluoro-Methyl-Tyrosine (18F-FMT), 18F-FAMT (L-[3-18F] (18)F-Fluorothymidine (18F-FLT)), (18)F-Fluoro-Azomycin-Arabinoside (18F-FAZA), (68)Ga-Neomannosylated-Human-Serum-Albumin (68Ga-MSA) (23), (68)Ga-Tetraazacyclododecane (68Ga-DOTA) (as theranostic agent), (11)C-Methionine (11C-MET), 18F-FPDOPA, ανβ3 integrin, 68Ga-RGD2, 64Cu-DOTA-RGD, 18F-Alfatide, Folate Radio tracers, and immuno-positron emission tomography radiopharmaceutical agents. Clinically approved procedures/radiopharmaceuticals agents: (18)F-Fluoro-Deoxy-Glucose (18F-FDG), (18)F-sodium fluoride (18F-NaF) (bone metastases), and (68)Ga-Tetraazacyclododecane (68Ga-DOTA). The quantitative determination and the change in radiopharmaceutical uptake parameters such as standard uptake value, metabolic tumor volume, total lesion glycolysis, FAZA tumor to muscle ratio, standard uptake value tumor to liver ratio, standard uptake value tumor to spleen ratio, standard uptake value maximum ratio, and the degree of hypoxia have prognostic and predictive (concerning the therapeutic outcome) value. They have been associated with the assessment of overall survival and disease free survival. With the positron emission tomography/computed tomography radiopharmaceuticals, the sensitivity and the specificity of the method have increased. Conclusion: In terms of lung cancer, positron emission tomography/computed tomography may have clinical application and utility (a) in personalizing treatment, (b) as a biomarker for the estimation of overall survival, disease free survival, and (c) apply a cost-effective patient approach because it reveals focuses of the disease, which are not found with the other imaging methods.

show abstract

Section: Sclc Stagingmentioning

confidence: 99%

Section: Sclc Stagingmentioning

confidence: 99%

Section: Sclc Investigationmentioning

confidence: 99%

“…PET/CT also changes the stage and the therapeutic management in 12%–26% of SCLC patients. 7 The global scientific literature does not provide enough data for SCLC and PET/CT.…”

Section: Sclc Investigationmentioning

confidence: 99%

“…Lung cancer can be diagnosed from the symptoms of primary tumor, local spread, metastases from inappropriate, or ectopic hormone excretion. 7 …”

Section: Diagnosismentioning

confidence: 99%

See 3 more Smart Citations

Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review

et al. 2020

View full text Add to dashboard Cite

show abstract

Thoracic Malignancies

Katal¹,

Clifford²,

Agrawal³

et al. 2023

Radiology‐Nuclear Medicine Diagnostic Imaging

View full text Add to dashboard Cite

Effectiveness of use of CT and SPECT with 99mTc-MAA and Ga-67 citrate in assessing the expansion of lung cancer in the determination of surgical intervention tactics

Agafonov

Амосов

Золотницкая

2019

Regional blood circulation and microcirculation

View full text Add to dashboard Cite

Introduction. Algorithms of the early detection of lung cancer remain a topic of discussion and the problem of timely assessment of the expansion of lung cancer remains unresolved.Objective – to determine if the combined use of contrastenhanced MDCT and 99mTcMAA SPECT and Gallium‐67 citrate SPECT is effective in assessing the expansion of lung cancer in the determination in the intervention tactics.Material and methods. In the study, radiologic examination was performed to 81 patients with lung cancer. Combined examinations included bolus contrastenhanced computed tomography (n = 81 patients), 99mTcMAA SPECT (n = 62 patients) and Gallium‐67 citrate SPECT (n = 9 patients).Results.According to MDCT data in most cases (n = 65 patients; 80 %) this method was able to diagnose the Tstage of the tumor; in some cases, the stage of malignancy was overestimated (n = 8 patients, 10 %), or underestimated (n = 8 patients, 10 %). According to the results of 99mТcМАА SPECT, it was possible to reliably determine the microcirculation disorders that were observed in the whole group of patients, while in 12 cases the impaired blood ﬂow was recorded only according to the results of 99mTcMAA SPECT and in 50 cases the severity of changes in blood ﬂow was more signifcant than according to MDCT. When analyzing Ga67 citrate SPECT data, in all 9 cases wholebody Ga67 citrate SPECT showed intense hot areas at the tumor region. It was also possible to show several mildly increased foci in the hilar lymph nodes in 6 cases, but in 3 cases the result was false positive.Conclusions. Bolus contrastenhanced computed tomography in most cases allows to correctly determine the Tstage of lung cancer and show tumor invasion into the surrounding tissues and vessels. At the same time, an additional 99mTcMAA SPECT study allows to clarify the degree of disturbance of the microvasculature in more detail. It is possible to supplement the assessment of regional metastasis by Gallium‐67 citrate SPECT, however, it is necessary to take into account the inﬂammatory nature of lymph node changes as a cause of falsepositive data.

show abstract

18F-FDG PET/CT in Lung Cancer

Cited by 3 publications

References 50 publications

Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review

Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review

Thoracic Malignancies

Effectiveness of use of CT and SPECT with 99mTc-MAA and Ga-67 citrate in assessing the expansion of lung cancer in the determination of surgical intervention tactics

Contact Info

Product

Resources

About